 Cytogenetic Analysis
"Cytogenetic Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
| Descriptor ID |
D020732
|
| MeSH Number(s) |
E01.370.225.500.385 E05.200.500.385 E05.242.385 E05.393.285
|
| Concept/Terms |
Cytogenetic Analysis- Cytogenetic Analysis
- Analyses, Cytogenetic
- Analysis, Cytogenetic
- Cytogenetic Analyses
- Molecular Cytogenetic Techniques
- Cytogenetic Technique, Molecular
- Cytogenetic Techniques, Molecular
- Molecular Cytogenetic Technique
- Technique, Molecular Cytogenetic
- Techniques, Molecular Cytogenetic
- Molecular Cytogenetic Technics
- Cytogenetic Technic, Molecular
- Cytogenetic Technics, Molecular
- Molecular Cytogenetic Technic
- Technic, Molecular Cytogenetic
- Technics, Molecular Cytogenetic
- Cytogenetic Technics
- Cytogenetic Technic
- Technic, Cytogenetic
- Technics, Cytogenetic
- Cytogenetic Techniques
- Cytogenetic Technique
- Technique, Cytogenetic
- Techniques, Cytogenetic
|
Below are MeSH descriptors whose meaning is more general than "Cytogenetic Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cytogenetic Analysis".
This graph shows the total number of publications written about "Cytogenetic Analysis" by people in UAMS Profiles by year, and whether "Cytogenetic Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2020 | 0 | 3 | 3 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2014 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2012 | 2 | 1 | 3 | | 2011 | 0 | 2 | 2 | | 2010 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 3 | 4 | | 2005 | 1 | 1 | 2 | | 2004 | 0 | 4 | 4 | | 2003 | 0 | 4 | 4 | | 2002 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytogenetic Analysis" by people in Profiles over the past ten years.
-
Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, Usmani SZ. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022 09; 198(6):988-993.
-
Atrash S, Flahavan EM, Xu T, Ma E, Karve S, Hong WJ, Jirau-Lucca G, Nixon M, Ailawadhi S. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J. 2022 03 23; 12(3):46.
-
Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 2020 11 03; 10(11):111.
-
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Nov 01; 6(11):1759-1765.
-
Maura F, Landgren O, Morgan GJ. Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clin Cancer Res. 2021 01 01; 27(1):15-23.
-
Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017 11 27; 7(12):634.
-
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 10; 22(10):1893-1899.
-
Cooley LD, Morton CC, Sanger WG, Saxe DF, Mikhail FM. Section E6.5-6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor-acquired chromosomal abnormalities. Genet Med. 2016 06; 18(6):643-8.
-
Mobley BC, Kumar M, Sanger WG, Nelson M, Nickols HH, Chambless LB, Gokden M. Papillary tumor of the pineal region with synchronous suprasellar focus and novel cytogenetic features. Hum Pathol. 2015 Aug; 46(8):1232-6.
-
Lai YY, Huang XJ, Li J, Zou P, Xu ZF, Sun H, Shao ZH, Zhou DB, Chen FP, Liu ZG, Zhu HL, Wu DP, Wang C, Zhang Y, Li Y, Hou M, Du X, Wang X, Li W, Lai YR, Zhou J, Zhou YH, Fang MY, Qiu L, Wang XM, Zhang GS, Jiang M, Liang YM, Zhang LS, Chen XQ, Bai H, Lin JY. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China. Leuk Res. 2015 May; 39(5):530-5.
-
Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015 Jan 29; 125(5):831-40.
-
Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014 Apr 17; 123(16):2504-12.
-
Vlachos A, Farrar JE, Atsidaftos E, Muir E, Narla A, Markello TC, Singh SA, Landowski M, Gazda HT, Blanc L, Liu JM, Ellis SR, Arceci RJ, Ebert BL, Bodine DM, Lipton JM. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome. Blood. 2013 Oct 03; 122(14):2487-90.
-
Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|